Custom Search

FDA Information

Rituximab was initially approved by the FDA in 1997 for lymphoma that was refractory to other chemotherapy regimens. The original approval followed the availability of the McLaughlin et al study data.

It is now standard therapy in the initial treatment of aggressive lymphomas (e.g. diffuse large B cell lymphoma) in combination with CHOP chemotherapy.


Why is this medication prescribed?

Other uses for this medicine

Dosage and using this medicine

What special precautions should I follow?

What should I do if I forget a dose?

What side effects can this medication cause?

What storage conditions are needed for this medicine?

In case of an emergency/overdose

Use of this site is subject to the following terms of use